Byler Julie, Harrison Rebecca, Fell Lindsey L
Department of Internal Medicine, Oregon Health & Science University, Portland, OR, USA.
Division of Hospital Medicine, School of Medicine, Oregon Health & Science University, Portland, OR, USA.
Am J Case Rep. 2021 May 8;22:e931616. doi: 10.12659/AJCR.931616.
BACKGROUND Rhabdomyolysis occurs when muscle injury leads to the release of muscle cell constituents into circulation, often leading to significant systemic complications. There are many causes of rhabdomyolysis, and the etiology is often multifactorial or unclear. Current data suggest that acute COVID-19 may cause muscle injury that can lead to rhabdomyolysis, particularly in cases of severe illness requiring prolonged hospitalization; however, data on the long-term effects of COVID-19 on the musculoskeletal system are lacking. CASE REPORT We present a case of a woman with generalized weakness 1 week following discharge from the hospital after a prolonged admission for severe COVID-19. She was found to have acute kidney injury and elevated creatine kinase (CK) of 1775 U/L (normal 36-234 U/L). Her home medications, including her statin, were held, but her CK continued to rise, peaking at 15 085 U/L, and she developed renal failure necessitating renal replacement therapy. A thorough work-up for the underlying etiology of her rhabdomyolysis was pursued, including testing for autoimmune myositis, statin-associated necrotizing autoimmune myositis, and a muscle biopsy, which were all unrevealing. Ultimately, the patient's rhabdomyolysis was determined to likely be secondary to a post-viral myopathy from COVID-19. A toxic myopathy from medication use or a delayed critical illness myopathy from her recent prolonged hospitalization could have also contributed. CONCLUSIONS This case highlights the wide differential diagnosis of rhabdomyolysis in the setting of recent COVID-19 and prolonged hospitalization. It demonstrates the possibility that muscle injury and resultant rhabdomyolysis may be a late complication of COVID-19 that is not yet fully described in the literature.
横纹肌溶解症是指肌肉损伤导致肌肉细胞成分释放到循环系统中,常引发严重的全身并发症。横纹肌溶解症的病因众多,且往往是多因素的或不明的。目前的数据表明,急性新冠病毒病(COVID-19)可能导致肌肉损伤,进而引发横纹肌溶解症,尤其是在需要长期住院治疗的重症病例中;然而,关于COVID-19对肌肉骨骼系统长期影响的数据尚缺乏。病例报告:我们报告一例女性病例,该患者因重症COVID-19长期住院,出院1周后出现全身无力。发现她患有急性肾损伤,肌酸激酶(CK)升高至1775 U/L(正常范围36 - 234 U/L)。停用了包括他汀类药物在内的家庭用药,但她的CK仍持续升高,最高达到15085 U/L,并发展为肾衰竭,需要进行肾脏替代治疗。对其横纹肌溶解症的潜在病因进行了全面检查,包括自身免疫性肌炎、他汀类药物相关坏死性自身免疫性肌炎检测以及肌肉活检,但均未发现异常。最终,确定该患者的横纹肌溶解症可能继发于COVID-19后的病毒感染后肌病。药物使用导致的中毒性肌病或近期长期住院引发的迟发性危重病性肌病也可能起了作用。结论:该病例突出了近期COVID-19和长期住院情况下横纹肌溶解症的广泛鉴别诊断。它表明肌肉损伤及由此导致的横纹肌溶解症可能是COVID-19的一种晚期并发症,而这在文献中尚未得到充分描述。